Trump Tells Drug Companies ‘Get It Done’ on Virus Treatments
(Bloomberg) -- President Donald Trump sought to show his personal engagement in the fight against coronavirus, meeting with drug company executives on Monday to elicit promises of new medicines and announcing he'll visit federal health agencies later in the week.
At the White House meeting, executives from Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline Plc, Sanofi, Pfizer Inc. and other manufacturers told Trump they were making rapid progress on vaccines and antivirals to combat the coronavirus, which has infected about 100 people in the country and killed six.
The manufacturers said they hope to have antiviral treatments ready within months and vaccines by next year. Gilead Chairman and Chief Executive Officer Daniel O'Day told Trump that his company may test a promising antiviral in Washington State, where all six deaths from the virus have occurred.
“It's a very optimistic meeting. I didn't realize you were that far advanced,” Trump said. “Get it done. We need it.”
Vice President Mike Pence said Trump will visit the National Institutes of Health in Bethesda, Maryland, on Tuesday and the Centers for Disease Control and Prevention in Atlanta later this week. At a campaign rally in Charlotte, North Carolina, on Monday evening, Trump promised that “we're working hard on it and we're going to come up with some really great solutions.
“We're going to reduce the severity of what's happening, the duration of the virus,” Trump said. “We will bring these therapies to market as rapidly as possible.”
Airport Screenings
Pence said at a briefing for reporters at the White House that South Korea has begun screening all passengers bound for the U.S. from any of their airports for infection. Italy will implement similar screening within 12 hours, Pence said.
The exit screening will entail “multiple temperature checks in the airports for people before they are boarding,” Pence said at a briefing for reporters with federal health officials.
The U.S. has restricted travel from China and Iran to prevent infected people from entering the country. Asked if those restrictions would be expanded, Pence said “the president was very clear we're going to follow the facts and listen to the experts every step of the way.”
“The American people should know that we are saying you should not travel to certain sections of Italy and South Korea,” Pence said. “We'll allow the caseload in those countries to define” that guidance is expanded.
The Washington deaths have been centered around a nursing home near Seattle in Kirkland, where there are a large number of suspected patients. In total, there are at least 18 cases in the state, with at least 14 in King County and four in Snohomish County.
A top U.S. disease expert said the coronavirus is likely becoming a pandemic, and New York Governor Andrew Cuomo said he expects more cases after the state identified its first patient.
To contact the reporter on this story: Jordan Fabian in Washington at jfabian6@bloomberg.net
To contact the editors responsible for this story: Alex Wayne at awayne3@bloomberg.net, John Harney
©2020 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.